The preliminary results of an open label, single arm, multicenter study (NCT03397654) encouraged the clinical development of the combination of pembrolizumab (anti-PD-1 mAb) and TACE in patients with intermediate-stage HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.